The Chac Foundation is an organisation created by a group of relatives, professionals and those directly or indirectly affected by the experience of Rare Diseases.
The Board of Trustees of the Foundation is made up of professionals with a long history and who collaborate selflessly with the foundation, each one contributing the best in their field of activity.
Corea Acanthocytosis (ChAc) is a neurodegenerative disease, a form of neuroacanthocytosis clinically characterised by a phenotype similar to Huntington’s disease (HD) that presents progressive neurological symptoms, including movement disorder, psychiatric manifestations, and cognitive disorders. It usually appears at the beginning of adulthood, at the age of 30 with cognitive or psychiatric symptoms. ChAc is currently untreated and treatment is purely symptomatic.
Images: ChAc Foundation
There are 1,000 cases diagnosed in the world and 50 in Spain. To date, there are not enough studies to develop a treatment to cure Corea Acanthocytosis, nor is there any treatment to help alleviate the pathologies caused by the relentless progress of this disease.
The Bosch Aymerich Foundation contributes to the ChAc Foundation for Research into Treatments for this disease by signing a three-year agreement to help new avenues of treatment for this rare disease to be studied.
The Spanish Federation of Diseases believes that Rare Disease pathologies currently affect a a large number of people, as according to the World Health Organisation (WHO), there are about 7,000 rare diseases affecting 7% of the world’s population. It is estimated that in Spain alone there are more than 3 million people with rare or infrequent diseases.
The collaboration agreement was signed on 19 June 2020 with Ms. Mª Pilar Tarragona, president of the CHAC-Researching to cure Foundation, Mrs. Elena Cabarrocas, patron of the Bosch Aymerich Foundation and Mr. Antoni Bosch patron of the Bosch Aymerich Foundation.